Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of Eptinezumab for the Preventive Treatment of Migraine
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Eptinezumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms Sunrise
- Sponsors Lundbeck A/S
- 22 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2022 Planned number of patients changed from 513 to 945.
- 05 Dec 2022 Planned End Date changed from 31 Jul 2023 to 11 Mar 2025.